Shea Meghan, Rangachari Deepa, Hallowell Robert W, Hollie Norris I, Costa Daniel B, VanderLaan Paul A
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Cancer Treat Res Commun. 2018;15:17-20. doi: 10.1016/j.ctarc.2018.02.004. Epub 2018 Feb 21.
Oncologists are increasingly managing drug-induced pneumonitis in lung cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors. To date only few studies on the topic have described both radiologic and pathologic findings in these patients. Here, we report a fatal case of immune checkpoint inhibitor-associated pneumonitis initially presenting with an organizing pneumonia, but who rapidly developed acute respiratory distress syndrome (confirmed histologically at the time of autopsy). As such, this case illustrates the need for clinicians to maintain a high index of suspicion for immune checkpoint inhibitor associated pneumonitis and have a low threshold to perform CT imaging in any symptomatic patient receiving checkpoint inhibition therapy. CLINICAL PRACTICE POINTS.
肿瘤学家越来越多地参与到对接受PD-1/PD-L1免疫检查点抑制剂治疗的肺癌患者的药物性肺炎的管理中。迄今为止,关于该主题的研究仅有少数描述了这些患者的影像学和病理学表现。在此,我们报告一例免疫检查点抑制剂相关肺炎的致命病例,该病例最初表现为机化性肺炎,但迅速发展为急性呼吸窘迫综合征(尸检时经组织学证实)。因此,该病例表明临床医生需要对免疫检查点抑制剂相关肺炎保持高度怀疑指数,并且对于任何接受检查点抑制治疗的有症状患者,进行CT成像的阈值要低。临床实践要点。